Disruption of the leptin signaling pathway within the heart causes left ventricular hypertrophy (LVH). Because human obesity is a syndrome of leptin resistance, which is not amenable to leptin treatment, the identification of parallel signal transduction pathways is of potential therapeutic value. Ciliary neurotrophic factor (CNTF), which acts parallel to leptin in the hypothalamus, is not previously recognized to have cardiac activity. We hypothesized that CNTF receptors are present on cardiomyocytes and their activation reverses LVH in both leptin-deficient ob͞ob and leptinresistant db͞db mice. The localization of CNTF receptors (CNTFR␣) to the sarcolemma in C57BL͞6, ob͞ob and db͞db was confirmed in situ with immunohistochemistry, and immunoblotting (60 and 40 kDa) on isolated myocytes. ob͞ob mice were randomly assigned to receive s.c. recombinant CNTF (CNTF Ax15; 0.1 mg⅐kg ؊1 per day; n ‫؍‬ 11) calorie-restriction (n ‫؍‬ 9), or feeding ad libitum (n ‫؍‬ 11). db͞db mice were allocated to three similar groups (n ‫؍‬ 8, 7, and 8, respectively) plus a leptin group (1 mg⅐kg ؊1 per day; n ‫؍‬ 7). Echocardiography showed that CNTFAx15 reduced cardiac hypertrophy [posterior wall thickness decreased by 29 ؎ 8% (P < 0.01) in ob͞ob and by 21 ؎ 3% in db͞db mice (P < 0.01)], which was consistent with the reduction of myocyte width. Western blotting showed that leptin and CNTF Ax15 activated Stat3 and ERK1͞2 pathway in cultured adult mice cardiomyocytes and cardiac tissue from in ob͞ob and db͞db mice. Together, these findings support the role of a previously undescribed signaling pathway in obesityassociated cardiac hypertrophy and have therapeutic implications for patients with obesity-related cardiovascular disease and other causes of LVH.
L
eft ventricular hypertrophy (LVH) and its subsequent progression to congestive heart failure represents a major cause of morbidity and mortality in the United States (1) . Obesity, an important mediator of LVH (2) , results from either deficiency of or receptor insensitivity to leptin (3) (4) (5) , a hormone that regulates appetite and energy metabolism (6) . We have previously demonstrated that both leptin deficiency and resistance contribute to LVH in murine models (7) . Additionally, we showed regression of LVH with leptin repletion in leptin-deficient ob͞ob mice. However, because the majority of human obesity is associated with hyperleptinemia and leptin resistance (4, 8, 9) that is unresponsive to leptin treatment, we sought to identify an alternate signaling axis that regulates cardiac architecture. Here we address this issue with ciliary neurotrophic factor (CNTF), which activates a related signaling pathway to leptin and has similar effects on body weight and metabolism (10) (11) (12) . The CNTF receptor (CNTFR) complex closely resembles the leptin receptor (ObR) structurally and has a similar distribution in the hypothalamic nuclei associated with regulation of feeding and body weight (13, 14) . Both receptors are members of the gp130 cytokine family of receptors. The CNTF receptor is a trimeric receptor complex with a CNTF binding component (CNTFR␣), a leukemia inhibitory factor ␤ subunit, and the signal transducer of IL-6 (gp130) (15) . Support for parallels between leptin and CNTF signaling pathways include structural homology between ObR and the gp130 subunit of the CNTFR (16) as well as activation of similar signal transduction pathways such as the Janus kinase-signal transducer and activator of transcription pathway (17) (18) (19) ). Thus, we tested whether CNTF receptors are present and functional in the heart and whether their activation would reverse established LVH in both ob͞ob and db͞db mice (10) .
Results
Presence of CNTFR␣ Receptors in Cardiac Tissue. To determine whether CNTFRs were present in the heart, we initially performed in situ peroxidase staining. The CNTFR (CNTFR␣) was visualized on myocytes in both longitudinal and transverse sections of C57bl͞6 wt mice hearts ( Fig. 1 a and c) . Double immunofluorescence staining for desmin and CNTFR␣ localized its presence to the sarcolemma (Fig. 1e) , which was further confirmed by immunoblots (60-kDa glycosylated and 40-kDa nonglycosylated bands) on isolated myocytes (Fig. 1g) . Mouse brain was used as positive control.
Regression of LVH in the ob͞ob Mice with CNTFAx15. Based on our earlier finding that leptin regresses established LVH in ob͞ob mice (ref. 7; Table 1), we hypothesized that CNTF Ax15 would mimic these effects on cardiac structure. CNTF Ax15 regressed cardiac hypertrophy, decreasing interventricular septal thickness by 20 Ϯ 3% (P ϭ 0.000035) posterior wall thickness by 29 Ϯ 8%, (P ϭ 0.000022), (Fig. 2 b and h) , and calculated left ventricular (LV) mass by 21 Ϯ 9%, (P ϭ 0.0077). In contrast and as previously shown, calorie restriction did not reduce LVH in these mice ( Table 2 ). The degree of regression with CNTF Ax15 restored wall thickness and left ventricular mass (LVM) essentially to normal. (Table 2 ) Interestingly, a reduction in LVM was noted in the calorie restricted group, but this decrease was due entirely to a smaller chamber size in these animals and, in the absence of reduced wall thickness, is unlikely to represent true regression of LVH.
Regression of Myocyte Width in the ob͞ob Mice with CNTFAx15. To determine whether the observed impact of CNTF Ax15 on LVH could be attributed to a regression of myocyte hypertrophy, we performed histological studies with hematoxylin͞eosin staining on ob͞ob mouse hearts (n ϭ 3-5) from each of the three groups (controls fed ad libitum, calorie restricted, or CNTF Ax15 treated), at the end of their treatment period. Myoycte width with CNTF Ax15 in the ob͞ob mice was reduced to 9.0 Ϯ 0.3 m compared to 11.3 Ϯ 0.5 m in those fed ad libitum (P Ͻ 0.001), and, in the calorie-restricted mice, 12.0 Ϯ 0.4 m (P Ͻ 0.001). There was no significant difference in cell size between the calorie restricted and ad libitum groups ( Fig. 3 b and h) 2 e and i), and calculated LV mass by 41 Ϯ 6% (P ϭ 0.00064), restoring cardiac architecture toward normal. CNTF Ax15 also significantly reduced LV end-systolic and -diastolic dimensions (P ϭ 0.042 and 0.013, respectively) ( Table 3) . Importantly, as predicted on the basis of an absent leptin receptor, leptin did not change LV wall thickness or LVM in db͞db mice (Table 3) . However, LVM was decreased in the calorie-restricted group, but, as discussed earlier, this reduction is most likely attributable to a decrease in chamber size.
Regression of Myocyte Width in the db͞db Mice with CNTFAx15.
Assessment of myocyte width in db͞db mice by hematoxylin͞ eosin staining showed that only CNTF Ax15 regressed toward normal (9.3 Ϯ 0.3 microns), in comparison to leptin-treated (12.6 Ϯ 0.6 microns; P Ͻ 0.001), calorie-restricted (10.8 Ϯ 0.4 microns; P Ͻ 0.05) and ad libitum controls (11.4 Ϯ 0.5 microns; P Ͻ 0.01) ( Fig. 3 e and i) .
CNTF Ax15 Signal Transduction. To determine whether CNTF Ax15 and leptin activated similar signal transduction pathways in isolated cardiac myocytes, the activation of STAT3, ERK1͞2 and JNK pathways, and calcineurin (CaN) signaling was determined. CNTF Ax15 and leptin produced near-identical phosphorylation of STAT3 (Fig. 4a) . Similarly, CNTF Ax15 and leptin both led to the phosphorylation of ERK1͞2, although the potency of this effect was greater with CNTF Ax15 (Fig. 4b) . Neither CNTF Ax15 nor leptin affected JNK phosphorylation or CaN levels in isolated myocytes (Fig. 5 ). In terms of chronic 4-week therapy, the predominant effect was an increase in STAT3 phosphorylation and protein expression after CNTF Ax15 treatment. Although the p-STAT3͞STAT3 ratio was not increased with CNTF Ax15 , the overall STAT3 phosphorylation and total STAT3 abundance were higher in cardiac tissue from Axokine-treated ob͞ob (Fig. 4c ) and db͞db mice (Fig. 4d) . CNTF Ax15 treatment resulted in a similar effect on the ERK1͞2 pathway ( Fig. 6 a and  b) . As expected, leptin did not produce this effect in db͞db mice lacking the leptin receptor. Consistent with the isolated cardiomyocyte data, JNK phosphorylation and CaN protein level were not increased in the cardiac tissue. However, total JNK protein expression was augmented ( Fig. 6 c and d) .
Discussion
The major finding of this study is that the CNTF signaling pathway, which is known to activate a parallel signal transduction pathway to leptin in the hypothalamus, has important cardiac bioactivity. The CNTF receptor is present in the cardiac sarcolemma, and its activation, like leptin (7), regresses established LVH in leptindeficient mice. Importantly, CNTF Ax15 signaling has similar cardiac effects in mice with leptin receptor dysfunction. CNTF Ax15 influences signal transduction in isolated cardiac myocytes supporting a role for direct effects on the heart, activating both the phosphorylation of STAT3 and ERK1͞2. These findings have therapeutic implications given that the majority of human obesity is due to leptin resistance rather than leptin deficiency (4, 8, 9) . The role of leptin or its deficiency in mediating cardiac hypertrophy is controversial. We (7) have previously demonstrated that leptin deficiency contributes to LVH in vivo in intact ob͞ob mice with established LVH. On the other hand, in normal neonatal myocytes, exposure to leptin in vitro stimulates growth or hypertrophy (21, 22) . However, these findings are not incompatible with each other, as the observed dichotomy could easily arise because of differences in milieu. For example, neonatal cells physiologically undergo rapid growth under the inf luence of normal trophic factors, unlike adult myocytes. Syed et al. (23) recently provided proof of principle for this concept and showed that although certain genes produced changes in ventricular structure and function in neonatal cells, they had no impact on the adult myocardium. These findings suggest that physiologic differences in characteristics between neonatal and adult myocytes play an important role in their response to external stimuli and the net result may even be the opposite (23) .
CNTF Ax15 and leptin stimulated the phosphorylation of STAT3 acutely in cardiac myocytes and augmented total STAT3 levels in association with regression of hypertrophy in the ob͞ob and db͞db mice. STAT3 phosphorylation is attributed with a prohypertrophic effect in neonatal myocytes (24, 25) but also a cardioprotective antiremodeling effect (26, 27) . The present data support the dominance of the cardioprotective effects in this setting. Importantly, these results also demonstrate that CNT-F Ax15 and leptin directly activate similar signal transduction cascades within cardiac myocytes.
Recent epidemiologic studies support our paradigm as well. In a study conducted in healthy individuals free from cardiovascular disease, Pladevall et al. (28) showed that leptin deficiency was associated with increased left ventricular mass index, thus demonstrating that leptin has an antihypertrophic effect in the presence of an intact signaling pathway. Although some older studies showed a positive correlation between leptin and LVH when adjusting for body mass index (BMI) (29) , others have highlighted that this positive correlation is completely abrogated after adjusting for BMI (30) . Nonetheless, it is well established that obesity in clinical populations is associated with elevated leptin primarily due to leptin resistance, implying depressed downstream signaling despite increased leptin levels (4, 8, 9) . Our current results further substantiate that like leptin, the CNTF signaling pathways regress established LVH, probably by restoring downstream leptin or leptin-like signaling, and offer additional support to the paradigm that leptin signaling deficiency contributes to the development of LVH in obesity in vivo.
Several points warrant mention. The potential mechanism of action of CNTF Ax15 is complex. Although we have demonstrated direct actions within the heart (such as STAT3 and ERK1͞2 activation), we cannot exclude the possibility of systemic effects. For example, central nervous system effects of CNTF Ax15 may directly influence the heart. Indeed, the leptin͞leptin-receptor axis is known to activate the central nervous system (31, 32) and to mediate metabolic actions by acting centrally. Additionally, it is possible that the receptors are not present solely on cardiac myocytes but also on other tissues, such as cardiac ganglia, implying the possibility of paracrine signaling effects within the heart. Nonetheless, our finding that CNTF Ax15 causes a regression of established LVH not only in leptin-deficient animals but also in those lacking a functional leptin receptor in the context of stimulating signal transduction within cardiac myocytes establishes the existence of a previously unrecognized pathway in the regulation of LVH.
Our findings identify a cardiac signal transduction pathway in obesity related cardiac hypertrophy. Because the majority of human obesity is associated with leptin resistance, further evaluation of CNTF Ax15 for potential therapeutic applications in the treatment of LVH in patients with leptin resistance may be fruitful.
Materials and Methods
Animals. We used ob͞ob, db͞db, and C57BL͞6 WT mice obtained from The Jackson Laboratory. Animal treatment and care was provided in accordance with institutional guidelines. All animals were housed under diurnal lighting conditions and allowed food and tap water ad libitum except the calorie-restricted groups, where each mouse received 1 g of food per day as described below. The Animal Care and Use Committee of The Johns Hopkins University approved all protocols.
Isolated Myocyte Preparation. Cardiac myocytes were isolated and prepared from mouse hearts as described in detail by Khan et al. (33) . Myocytes were plated with 80% confluency into 35-mm dishes (Falcon) containing a serum-free 500 M Ca 2ϩ containing isolation solution for 30 min. Myocytes were then treated with 50 ng͞l leptin and 50 ng͞l CNTF Ax15 for various periods of time.
Treatment by Administration of Exogenous Leptin, CNTFAx15, and
Calorie Restriction. Five-to 6-month-old ob͞ob and db͞db mice were randomly assigned to three or four groups, respectively, and treated for a period of 4 weeks. The first group received CNTF Ax15 , the second group was calorie-restricted so as to lose similar weight as treated animals, and the third group was fed ad libitum as controls. Additional db͞db mice were assigned to a fourth group to receive leptin. Mice in the CNTF Ax15 group were injected daily with recombinant mouse CNTF Ax15 (Regeneron Pharmaceuticals, Tarrytown, NY, 0.1 mg⅐kg Ϫ1 per day), whereas the leptin group were injected with recombinant mouse leptin (R & D Systems, 1 mg⅐kg Ϫ1 per day). The calorie restriction regimen consisted of 1 g of food per day, which was previously determined to result in a similar rate of weight loss to leptin or CNTF Ax15 administration at these doses (7) . The calorie-restricted groups and the ad libitum controls were injected with Dulbecco's PBS.
Echocardiography. To examine the impact of CNTF Ax15 and leptin on established LVH (Table 1) in leptin-deficient ob͞ob mice (7), we performed echocardiograms on mice randomized to one of three treatment groups: CNTF Ax15 (n ϭ 11, 5-6 months old, weight: 70 Ϯ 2 g), calorie restriction (n ϭ 9, 5-6 months old, weight: 71 Ϯ 2 g), and controls fed ad libitum (n ϭ 11, 5-6 months old, weight: 70 Ϯ 1 g). We also investigated the effects of CNTF Ax15 (n ϭ 8, 5-6 months old, weight: 60 Ϯ 2 g), calorie restriction (n ϭ 8, 5-6 months old, weight: 60 Ϯ 2 g), leptin (n ϭ 7, 5-6 months old, weight: 58 Ϯ 2 g), and controls fed ad libitum (n ϭ 7, 5-6 months old, weight: 59 Ϯ 1 g) on LVH after a 4-week treatment period in db͞db mice. Echocardiography was performed on conscious unanesthetized mice at baseline and repeated at the end of the treatment period. The individual performing the echocardiograms was blinded to the group assignments. Mice were trained before each study until they were relaxed for the procedure. Studies were performed by using a Sequoia C256 (Siemens, Mountain View, CA) echocardiogram with a 15 MHz linear array transducer. Interventricular septal and posterior wall thicknesses, as well as diastolic and systolic LV dimensions were recorded from M-mode images by using averaged measurements from three to five consecutive cardiac cycles. LVM was calculated by using LVM ϭ 1.055 ϫ (interventricular septal thickness in diastole thickness ϩ posterior wall thickness ϩ left ventricular end diastolic diameter) 3 Ϫ (left ventricular end diastolic diameter) 3 .
Histology. Mice hearts were harvested, washed with ice-cold PBS, sectioned, and either fixed in 10% formalin or in Streck's tissue fixative (Streck Laboratories, Omaha, NE) overnight and were paraffin embedded the next morning. Histochemical and immunohistochemical studies were carried out on 4-mthick sections.
Histochemical Staining. Hematoxylin͞eosin staining were performed to evaluate cell sizes. Myocyte diameters were measured in regions of myocardium with parallel myocyte fascicles in longitudinal sections by using IMAGEJ (National Institutes of Health). Representative high-powered-fields distributed around the myocardium were used to measure 7-29 cells from each heart. The individual analyzing histology data were blinded to the group assignments.
Immunohistochemistry. For antigen retrieval, the sections were steamed with Target Retrieval System (DAKO) for 20 min, before blocking with avidin and biotin blocking solutions (DAKO) and 10% normal goat serum. The receptor was stained with a monoclonal mouse anti-CNTFR-␣ (BD Pharmingen, no. 558783; 1:100 dilution). After washing, the secondary antibody (biotinylated goat anti-mouse Ig; E0433, DAKO; 1:400 dilution) and streptavidin peroxidase (Vectastain, Vector Laboratories) were applied.
The peroxidase activity was developed 5 min with 0.066% diaminobenzidine͞0.01% H 2 O 2 ͞2.5% NiSO 4 . Slides were cleared in xylene, coverslipped, and viewed on a Zeiss Axiovert 200 microscope equipped with 510-Meta confocal laser scanning module.
Fluorescence. Tissue section were rinsed with ice-cold PBS twice for 2 min and were blocked with 10% goat serum for 30 min. The slides were incubated with rabbit anti-human desmin antibody (Accurate Chemical & Scientific, no. YMPS31) and monoclonal mouse anti-CNTFR-␣ antibody (BD Pharmingen, no. 558783) at 4°C overnight. After washing, FITC and rhodamine coupled secondary antibodies (Vector Laboratories) were applied for 45 min at room temperature. Tissue slide were washed and coverslipped with mounting medium and viewed.
Western Blots. Hearts from ob͞ob, db͞db, and WT mice were harvested after cervical dislocation and rinsed in isolation buffer to remove excess blood. Cells were isolated as described by Minhas et al. (34) . Isolated myocytes were homogenized in cold cell lysis buffer (Cell Signaling Technology, Beverly, MA) with one tablet of complete protease inhibitors (Roche Diagnostics) per 10 ml of buffer. The protein lysate was quantitated with the bicinchonic assay (Pierce), and 30 -50 g of total protein was separated in 4 -12% Bis-Tris⅐HCl polyacrylamide gels (Invitrogen). The proteins were transferred onto nitrocellulose membranes and blocked for 1 h with 5% nonfat milk. After blocking, the membranes were incubated with monoclonal anti-CNTFR␣ antibody (1:1,000, BD Pharmingen), polyclonal anti-phospho-STAT3 antibody, polyclonal antiphospho-ERK1͞2 antibodies, polyclonal anti-phospho-JNK antibodies (all 1:1,000, Cell Signaling Technology), or monoclonal anti-calcineurin antibodies (1:2,000, Chemicon International) overnight at 4°C. Immunoblots were detected by using enhanced chemiluminescent kits (SuperSignal, Pierce)
